Effects of 3,4-methylenedioxymethamphetamine (MDMA) and its main metabolites on cardiovascular function in conscious rats

British Journal of Pharmacology

Volumn 171, Issue 1, 2014, Pages 83-91

  Schindler, Charles W ^a   Thorndike, Eric B ^a   Blough, Bruce E ^b   Tella, Srihari R ^c   Goldberg, Steven R ^a   Baumann, Michael H ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b RTI INTERNATIONAL   (United States)

^c Drug Enforcement Administration   (United States)

Author keywords

BP; heart rate; MDMA metabolites; noradrenergic; telemetry

Indexed keywords

3 O METHYL ALPHA METHYLDOPAMINE; 3,4 DIHYDROXYAMPHETAMINE; 3,4 DIHYDROXYMETHAMPHETAMINE; 3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXY 3 METHOXYMETHAMPHETAMINE; AMPHETAMINE DERIVATIVE; DRUG METABOLITE; PROPRANOLOL; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR FUNCTION; CONSCIOUSNESS; CONTROLLED STUDY; DRUG EFFECT; HEART RATE; LOCOMOTION; MALE; MOTOR ACTIVITY; NONHUMAN; PRIORITY JOURNAL; RACEMIC MIXTURE; RAT; TACHYCARDIA; TELEMETRY;

BP; HEART RATE; MDMA METABOLITES; NORADRENERGIC; TELEMETRY;

3,4-METHYLENEDIOXYAMPHETAMINE; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CONSCIOUSNESS; DEOXYEPINEPHRINE; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HALLUCINOGENS; HEART RATE; MALE; METABOLIC DETOXICATION, PHASE I; METHAMPHETAMINE; MOTOR ACTIVITY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RATS; RATS, SPRAGUE-DAWLEY; TELEMETRY; TIME FACTORS;

EID: 84890284230     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12423     Document Type: Article

References (48)

1. Badon LA, Hicks A, Lord K, Ogden BA, Meleg-Smith S, Varner KJ, (2002). Changes in cardiovascular responsiveness and cardiotoxicity elicited during binge administration of Ecstasy. J Pharmacol Exp Ther 302: 898-907.
2. Bankson MG, Cunningham KA, (2001). 3,4-Methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interactions. J Pharmacol Exp Ther 297: 846-852.
3. Bankson MG, Cunningham KA, (2002). Pharmacological studies of the acute effects of (+)-3,4-methylenedioxymethamphetamine on locomotor activity: role of 5-HT(1B/1D) and 5-HT(2) receptors. Neuropsychopharmacology 26: 40-52.
4. Baumann MH, Rothman RB, (2009). Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA). Int Rev Neurobiol 88: 257-296.
5. Baumann MH, Clark RD, Rothman RB, (2008). Locomotor stimulation produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brain. Pharmacol Biochem Behav 90: 208-217.
6. Baumann MH, Zolkowska D, Kim I, Scheidweiler KB, Rothman RB, Huestis MA, (2009). Effects of dose and route of administration on pharmacokinetics of (+ or -)-3,4-methylenedioxymethamphetamine in the rat. Drug Metab Dispos 37: 2163-2170.
7. Bexis S, Docherty JR, (2006). Effects of MDMA, MDA and MDEA on blood pressure, heart rate, locomotor activity and body temperature in the rat involve alpha-adrenoceptors. Br J Pharmacol 147: 926-934.
8. Branch CA, Knuepfer MM, (1992). Adrenergic mechanisms underlying cardiac and vascular responses to cocaine in conscious rats. J Pharmacol Exp Ther 263: 742-751.
9. Drug Abuse Warning Network (2010). 2009: Selected Tables of National Estimates of Drug-Related Emergency Department Visits. Center for Behavioral Health Statistics and Quality, SAMHSA: Rockville, MD.
10. Escobedo I, O'Shea E, Orio L, Sanchez V, Segura M, de la Torre R, et al. (2005). A comparative study on the acute and long-term effects of MDMA and 3,4-dihydroxymethamphetamine (HHMA) on brain monoamine levels after i.p. or striatal administration in mice. Br J Pharmacol 144: 231-241.
11. Escubedo E, Abad S, Torres I, Camarasa J, Pubill D, (2011). Comparative neurochemical profile of 3,4-methylenedioxymethamphetamine and its metabolite alpha-methyldopamine on key targets of MDMA neurotoxicity. Neurochem Int 58: 92-101.
12. Fitzgerald JL, Reid JJ, (1994). Sympathomimetic actions of methylenedioxymethamphetamine in rat and rabbit isolated cardiovascular tissues. J Pharm Pharmacol 46: 826-832.
13. Fonsart J, Menet MC, Debray M, Hirt D, Noble F, Scherrmann JM, et al. (2009). Sprague-Dawley rats display sex-linked differences in the pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolite 3,4-methylenedioxyamphetamine (MDA). Toxicol Appl Pharmacol 241: 339-347.
14. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI, (2003). The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacol Rev 55: 463-508.
15. Halpern P, Moskovich J, Avrahami B, Bentur Y, Soffer D, Peleg K, (2011). Morbidity associated with MDMA (ecstasy) abuse: a survey of emergency department admissions. Hum Exp Toxicol 30: 259-266.
16. Hysek CM, Vollenweider FX, Liechti ME, (2010). Effects of a beta-blocker on the cardiovascular response to MDMA (Ecstasy). Emerg Med J 27: 586-589.
17. Hysek CM, Simmler LD, Ineichen M, Grouzmann E, Hoener MC, Brenneisen R, et al. (2011). The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ('ecstasy') in humans. Clin Pharmacol Ther 90: 246-255.
18. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE, (2011). Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings. Institute for Social Research, The University of Michigan: Ann Arbor, MI.
19. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: Reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
20. Kiritsy-Roy JA, Halter JB, Gordon SM, Smith MJ, Terry LC, (1990). Role of the central nervous system in hemodynamic and sympathoadrenal responses to cocaine in rats. J Pharmacol Exp Ther 255: 154-160.
21. Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, Huestis MA, (2008a). Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration. J Clin Psychopharmacol 28: 432-440.
22. Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, Huestis MA, (2008b). Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. Ther Drug Monit 30: 320-332.
23. Lester SJ, Baggott M, Welm S, Schiller NB, Jones RT, Foster E, et al. (2000). Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlled trial. Ann Intern Med 133: 969-973.
24. Liechti ME, Vollenweider FX, (2000a). Acute psychological and physiological effects of MDMA ('Ecstasy') after haloperidol pretreatment in healthy humans. Eur Neuropsychopharmacol 10: 289-295.
25. Liechti ME, Vollenweider FX, (2000b). The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers. J Psychopharmacol 14: 269-274.
26. Liechti ME, Vollenweider FX, (2001). Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum Psychopharmacol 16: 589-598.
27. Liechti ME, Gamma A, Vollenweider FX, (2001a). Gender differences in the subjective effects of MDMA. Psychopharmacology (Berl) 154: 161-168.
28. Liechti ME, Geyer MA, Hell D, Vollenweider FX, (2001b). Effects of MDMA (ecstasy) on prepulse inhibition and habituation of startle in humans after pretreatment with citalopram, haloperidol, or ketanserin. Neuropsychopharmacology 24: 240-252.
29. Mas M, Farre M, de la Torre R, Roset PN, Ortuno J, Segura J, et al. (1999). Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 290: 136-145.
30. Matthews JN, Altman DG, Campbell MJ, Royston P, (1990). Analysis of serial measurements in medical research. BMJ 300: 230-235.
31. Maurer HH, Bickeboeller-Friedrich J, Kraemer T, Peters FT, (2000). Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('Ecstasy'). Toxicol Lett 112-113: 133-142.
32. McDaid J, Docherty JR, (2001). Vascular actions of MDMA involve alpha1 and alpha2-adrenoceptors in the anaesthetized rat. Br J Pharmacol 133: 429-437.
33. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
34. Mueller M, Yuan J, Felim A, Neudorffer A, Peters FT, Maurer HH, et al. (2009). Further studies on the role of metabolites in (+/-)-3,4- methylenedioxymethamphetamine-induced serotonergic neurotoxicity. Drug Metab Dispos 37: 2079-2086.
35. O'Cain PA, Hletko SB, Ogden BA, Varner KJ, (2000). Cardiovascular and sympathetic responses and reflex changes elicited by MDMA. Physiol Behav 70: 141-148.
36. Scheidweiler KB, Ladenheim B, Cadet JL, Huestis MA, (2010). Mice lacking multidrug resistance protein 1a show altered dopaminergic responses to methylenedioxymethamphetamine (MDMA) in striatum. Neurotox Res 18: 200-209.
37. Schindler CW, (1996). Cocaine and cardiovascular toxicity. Addict Biol 1: 31-47.
38. Schindler CW, Tella SR, Goldberg SR, (1992a). Adrenoceptor mechanisms in the cardiovascular effects of cocaine in conscious squirrel monkeys. Life Sci 51: 653-660.
39. Schindler CW, Zheng JW, Tella SR, Goldberg SR, (1992b). Pharmacological mechanisms in the cardiovascular effects of methamphetamine in conscious squirrel monkeys. Pharmacol Biochem Behav 42: 791-796.
40. Segura M, Ortuno J, Farre M, McLure JA, Pujadas M, Pizarro N, et al. (2001). 3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. Chem Res Toxicol 14: 1203-1208.
41. Shenouda SK, Carvalho F, Varner KJ, (2010). The cardiovascular and cardiac actions of ecstasy and its metabolites. Curr Pharm Biotechnol 11: 470-475.
42. Suarez RV, Riemersma R, (1988). 'Ecstasy' and sudden cardiac death. Am J Forensic Med Pathol 9: 339-341.
43. Tancer M, Johanson CE, (2007). The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 189: 565-573.
44. Tella SR, Schindler CW, Goldberg SR, (1999). Cardiovascular responses to cocaine self-administration: acute and chronic tolerance. Eur J Pharmacol 383: 57-68.
45. de la Torre R, Farre M, (2004). Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol Sci 25: 505-508.
46. de la Torre R, Farre M, Roset PN, Pizarro N, Abanades S, Segura M, et al. (2004). Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit 26: 137-144.
47. Vandeputte C, Docherty JR, (2002). Vascular actions of 3,4-methylenedioxymethamphetamine in alpha(2A/D)-adrenoceptor knockout mice. Eur J Pharmacol 457: 45-49.
48. Vollenweider FX, Gamma A, Liechti M, Huber T, (1998). Psychological and cardiovascular effects and short-term sequelae of MDMA ('ecstasy') in MDMA-naive healthy volunteers. Neuropsychopharmacology 19: 241-251.